Navigating Ozempic-#Ozempic

About Navigating Ozempic-#Ozempic

The "Navigating Ozempic" podcast is a deep dive into the world of Ozempic, a medication widely discussed for its role in weight management and diabetes control. This informative and engaging series is designed to illuminate every facet of Ozempic, from its medical applications to its impact on lifestyle and health. Each episode features a blend of expert interviews, real-life success stories, and practical advice, offering listeners comprehensive insights into how Ozempic works, its benefits, potential side effects, and the latest research findings.Listeners can expect to hear from healthcare professionals, researchers, and individuals who share their personal journeys with Ozempic, providing a balanced and nuanced perspective on the drug's role in managing health conditions. The podcast also navigates through tips for optimizing health outcomes while on Ozempic, including dietary recommendations, exercise routines, and strategies for integrating the medication into daily life.Whether you're considering Ozempic, already using it, or simply curious about its effects, "Navigating Ozempic" aims to equip you with the knowledge and tools to make informed decisions about your health. It's an essential resource for anyone looking to understand the complexities of this medication and how it can be part of a broader approach to achieving and maintaining optimal health. This content was created in partnership and with the help of Artificial Intelligence AI.

Publisher

Liquid Studios

Category

education · health & fitness

Language

en

Explicit

No

First episode

19 Mar 2024

Latest episode

17 Oct 2026

Latest episodes

149 episodes in the feed.

1. 

   17 Oct 2026

   # Semaglutide Study Explores Addiction Treatment; Safety Concerns Emerge

   # Navigating Ozempic: Addiction Trial, Vision Risk Warning & Ireland's Wegovy Decision (October 17, 2026) **Breaking Ozempic and semaglutide news you need to know—from a potential addiction treatment breakthrough to a serious new eye condition warning.** In this episode of Navigating Ozempic, we break down three major developments shaking up the semaglutide landscape: 🔬 **Addiction Treatment Trial**: Allegheny County, Pennsylvania is launching a $13.3 million clinical trial to study whether semaglutide can help treat alcohol and opioid use disorders. Learn how this 1,200-person, 52-week study could change addiction care—and why researchers urge caution before jumping to conclusions. 💶 **Ireland's Wegovy Access Decision**: Ireland's National Centre for Pharmacoeconomics has deemed Wegovy cost-effective for certain overweight patients, with a potential five-year price tag of €4.4 billion for the health system. We unpack what this means for obesity treatment access and the tough tradeoffs health systems face. ⚠️ **Critical Eye Safety Alert**: The European Medicines Agency has linked semaglutide to a rare but serious eye condition called NAION, which can cause sudden vision loss. We explain what the 1-in-10,000 risk estimate actually means, why Novo Nordisk disputes the findings, and what symptoms require immediate medical attention. Plus: the truth behind "Ozempic face," emerging research on heart, kidney, and liver benefits, and why self-treating with unregulated semaglutide products is never worth the risk. Whether you're currently taking Ozempic, Wegovy, or Rybelsus, considering treatment, or simply following the science, this episode delivers clear, evidence-based updates without the hype. **Topics covered:** Ozempic news, semaglutide safety, Wegovy cost-effectiveness, NAION eye condition, addiction treatment research, weight loss medication side effects, GLP-1 drugs, diabetes treatment updates 🎧 Subscribe to Navigating Ozempic for weekly, fact-checked updates on the medicine changing modern healthcare. *A Quiet Please production. Visit quietplease.ai for more. Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai

2. 

   10 Oct 2026

   Ozempic's Promise and Pitfalls: Safety, Caution, and Unanswered Questions

   # Ozempic News Roundup: Safety Warnings, Vision Risks, Counterfeit Drugs & Anti-Aging Research **Episode Description:** Ozempic and semaglutide are back in the headlines—and this week's developments demand attention from anyone considering or currently using GLP-1 medications. In this episode of *Navigating Ozempic*, we break down five critical stories reshaping the conversation around semaglutide, tirzepatide, and Mounjaro. **What You'll Learn:** - **Global safety alert**: Namibia's Ministry of Health issues new guidance on ethical prescribing and monitoring for semaglutide and tirzepatide amid surging demand - **Counterfeit drug danger**: Medical Daily investigates online sellers offering cheap "research-grade" semaglutide—some linked to chemicals used in fentanyl production—and why the FDA considers these products unapproved and potentially dangerous - **Vision and pancreatitis risks**: NPR's deep dive into nearly 2,000 pancreatitis cases and 1,000 reports of sudden vision loss (NAION) tied to GLP-1 medications since 2024 - **New pediatric guidelines**: The WHO's first-ever global recommendations for treating childhood obesity, including strict limits on medication use in children and teens - **Nutrition during weight loss**: Why reduced appetite on Ozempic may lead to protein, vitamin, and hydration deficiencies—and what dietitians recommend - **Muscle preservation research**: A promising phase 2 study on trevogrumab, designed to protect lean muscle mass during semaglutide-driven weight loss - **Anti-aging buzz**: Novo Nordisk and Eli Lilly's preliminary research suggesting semaglutide may slow biological aging markers by 2-4 years—and why these early findings need serious scrutiny - **Future of gener Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai

3. 

   3 Oct 2026

   Ozempic's Muscle Loss, Heart Benefits, and Safety Concerns Dominate Research Debate

   **Ozempic News Update: Muscle Preservation, Heart Health Data, Counterfeit Warnings & More** Ozempic is back in the headlines—and this episode of *Navigating Ozempic* breaks down everything you need to know from the past 72 hours of semaglutide research and safety news. In this episode, we cover: 🔬 **Muscle Preservation Breakthrough** – New data from Regeneron's trevogrumab trial, presented at the European Association for the Study of Diabetes meeting in Milan, shows promising results for preserving lean mass during semaglutide treatment—plus what this means for the future of weight-loss therapy. 💊 **Oral Semaglutide Switch Study** – A real-world analysis of patients transitioning from injectable to daily oral semaglutide reveals meaningful weight loss outcomes, with important caveats about study limitations. ❤️ **Cardiovascular Comparison** – Novo Nordisk's new analysis comparing higher-dose Ozempic to tirzepatide (Mounjaro) shows a notable difference in cardiovascular event risk—but what does "association" really mean here? 🩺 **Pancreatic Cancer Reassurance** – A large Nordic registry study of nearly 100,000 semaglutide users offers reassuring (though not definitive) safety data. 👁️ **Vision Safety Concerns** – We unpack ongoing lawsuits linking semaglutide to a rare eye condition, and what medical experts are actually saying about the risk. ⚠️ **Counterfeit Drug Alert** – Federal charges reveal a major counterfeit Ozempic scheme. Learn how to protect yourself and spot fake medication before it's too late. 📈 **The GLP-1 Boom** – New Gallup data shows GLP-1 medication use has nearly quadrupled in one year. What does this surge mean for healthcare systems, pricing, and patient safety? Whether you're currently taking Ozempic, considering it, Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai

Podcast Authority Score: 42 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

84

Social presence

0

YouTube

0

Engagement

0

Contact Navigating Ozempic-#Ozempic

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Shows with a similar audience

• 

  The Diary Of A CEO with Steven Bartlett

• 

  ZOE Science & Nutrition

• 

  The Mel Robbins Podcast

• 

  GLP-1 Hub: Support, Community, and Weight Loss

• 

  The No Sugarcoating Podcast

• 

  Today, Explained